請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/30997
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林慧玲(Fe-Lin Lin Wu) | |
dc.contributor.author | Chien-Chih Wu | en |
dc.contributor.author | 吳建志 | zh_TW |
dc.date.accessioned | 2021-06-13T02:24:34Z | - |
dc.date.available | 2009-01-01 | |
dc.date.copyright | 2007-02-13 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-01-30 | |
dc.identifier.citation | 1. Conrad SA, Rycus PT, Dalton H. Extracorporeal Life Support Registry Report 2004. Asaio J 2005;51(1):4-10.
2. Burket JS, Bartlett RH, Vander Hyde K, Chenoweth CE. Nosocomial infections in adult patients undergoing extracorporeal membrane oxygenation. Clin Infect Dis 1999;28(4):828-33. 3. Jones RN, Barry AL, Gardiner RV, Packer RR. The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective national surveillance trial of isolates from 40 medical centers. Diagnostic microbiology and infectious disease 1989;12(5):385-94. 4. Hsueh PR, Chen WH, Teng LJ, Luh KT. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 2005;26(1):43-9. 5. Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother 1996;40(5):1139-42. 6. Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol 2005;60(3):265-75. 7. Sezai A, Shiono M, Orime Y, et al. Major organ function under mechanical support: comparative studies of pulsatile and nonpulsatile circulation. Artif Organs 1999;23(3):280-5. 8. Roy BJ, Cornish JD, Clark RH. Venovenous extracorporeal membrane oxygenation affects renal function. Pediatrics 1995;95(4):573-8. 9. Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Koren G. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 1993;15(4):263-6. 10. Hill JD. Gibbon JH, Jr. Part I. The development of the first successful heart-lung machine. The Annals of thoracic surgery 1982;34(3):337-41. 11. Bartlett RH. Physiology of extracorporeal life support. In: Zwischenberger JB, Steinhorn RH, Bartlett RH, eds. Extracorporeal cardiopulmonary support in critical care (ECMO). 2 ed: Extracorpoeal Life Support Organization; 2000:41-2. 12. Bartlett RH. Physiology of extracorporeal life support. In: Zwischenberger JB, Steinhorn RH, Bartlett RH, eds. Extracorporeal cardiopulmonary support in critical care (ECMO). 2 ed: Extracorpoeal Life Support Organization; 2000:43-4. 13. Bartlett RH. Physiology of extracorporeal life support. In: Zwischenberger JB, Steinhorn RH, Bartlett RH, eds. Extracorporeal cardiopulmonary support in critical care (ECMO). 2 ed: Extracorpoeal Life Support Organization; 2000:54-8. 14. 柯文哲, 蔡壁如. ECMO手冊. 1 ed. 台北縣: 金名出版社; 2006. 15. Hirschl RB. Devices. In: Zwischenberger JB, Steinhorn RH, Bartlett RH, eds. Extracorporeal cardiopulmonary support in critical care (ECMO). 2 ed: Extracorpoeal Life Support Organization; 2000:209-12. 16. Hirschl RB. Devices. In: Zwischenberger JB, Steinhorn RH, Bartlett RH, eds. Extracorporeal cardiopulmonary support in critical care (ECMO). 2 ed: Extracorpoeal Life Support Organization; 2000:212-21. 17. 柯文哲. 體外膜氧合術:臨床應用與預後之預測 [博士論文]. 國立台灣大學臨床醫學研究所 2002:1-95. 18. Wilhelm MP, Estes L. Symposium on antimicrobial agents--Part XII. Vancomycin. Mayo Clin Proc 1999;74(9):928-35. 19. Hsueh PR, Teng LJ, Chen WH, et al. Increasing prevalence of methicillin-resistant Staphylococcus aureus causing nosocomial infections at a university hospital in Taiwan from 1986 to 2001. Antimicrob Agents Chemother 2004;48(4):1361-4. 20. Micromedex® Healthcare Series, Thomson Micromedex, Greenwood Village, Colorado.127(2006)In. 21. Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. J Antimicrob Chemother 2005;55 Suppl 2:ii5-ii13. 22. Lundstrom TS, Sobel JD. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid. Infect Dis Clin North Am 2000;14(2):463-74. 23. Watanakunakorn C, Tisone JC. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1982;22(5):903-5. 24. Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992;36(8):1766-9. 25. Ahmed A, Jafri H, Lutsar I, et al. Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1999;43(4):876-81. 26. MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 1998;20(5):473-7. 27. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42 Suppl 1:S35-9. 28. Ackerman BH. Clinical value of monitoring serum vancomycin concentrations. Clin Infect Dis 1994;19(6):1180-2. 29. Bauer LA. Vancomycin. In: Bauer LA, ed. Applied clinical pharmacokinetics. New York: McGraw-Hill; 2001:180-261. 30. Ambrose PJ, Winter ME. Vancomycin. In: Winter ME, ed. Basic clinical pharmacokinetics. 4 ed. Philadelphia: Lippincott Williams & Wilkins; 2004:451-76. 31. Farber BF, Moellering RC, Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983;23(1):138-41. 32. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25(4):679-87. 33. Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ, Hetsko CM. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 1990;10(6):378-82. 34. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995;15(1):85-91. 35. Burton M, Shaw L, JJ. S, WE. E. Applied pharmacokinetics and pharmacodynamics:Principles of therapeutic drug monitoring. 4 ed: Lippincott Williams&Wilkins; 2006. 36. Traber PG, Levine DP. Vancomycin Ototoxicity in patient with normal renal function. Ann Intern Med 1981;95(4):458-60. 37. Sivagnanam S, Deleu D. Red man syndrome. Crit Care 2003;7(2):119-20. 38. Wilson AP. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents 1998;10(2):143-52. 39. Matzke GR, Halstenson CE, Olson PL, Collins AJ, Abraham PA. Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis. Am J Kidney Dis 1987;9(5):422-5. 40. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986;11(4):257-82. 41. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988;32(6):848-52. 42. Wu G, Furlanut M. Prediction of serum vancomycin concentrations using one-, two- and three-compartment models with implemented population pharmacokinetic parameters and with the Bayesian method. The Journal of pharmacy and pharmacology 1998;50(8):851-6. 43. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994;16(5):513-8. 44. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984;25(4):433-7. 45. Krogstad DJ, Moellering RC, Jr., Greenblatt DJ. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol 1980;20(4 Pt 1):197-201. 46. Cutler NR, Narang PK, Lesko LJ, Ninos M, Power M. Vancomycin disposition: the importance of age. Clin Pharmacol Ther 1984;36(6):803-10. 47. Boeckh M, Lode H, Borner K, Hoffken G, Wagner J, Koeppe P. Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother 1988;32(1):92-5. 48. Golper TA, Noonan HM, Elzinga L, et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther 1988;43(5):565-70. 49. Brown N, Ho DH, Fong KL, et al. Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother 1983;23(4):603-9. 50. Marti R, Rosell M, Pou L, Garcia L, Pascual C. Influence of biochemical parameters of liver function on vancomycin pharmacokinetics. Pharmacol Toxicol 1996;79(2):55-9. 51. Aldaz A, Ortega A, Idoate A, Giraldez J, Brugarolas A. Effects of hepatic function on vancomycin pharmacokinetics in patients with cancer. Ther Drug Monit 2000;22(3):250-7. 52. Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987;31(3):393-7. 53. Macias WL, Mueller BA, Scarim SK. Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin Pharmacol Ther 1991;50(6):688-94. 54. Garaud JJ, Regnier B, Inglebert F, Faurisson F, Bauchet J, Vachon F. Vancomycin pharmacokinetics in critically ill patients. J Antimicrob Chemother 1984;14 Suppl D:53-7. 55. Garrelts JC, Peterie JD. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin Pharmacol Ther 1988;44(1):9-13. 56. Rybak MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990;34(5):792-5. 57. Brater DC, Bawdon RE, Anderson SA, Purdue GF, Hunt JL. Vancomycin elimination in patients with burn injury. Clin Pharmacol Ther 1986;39(6):631-4. 58. Rybak MJ, Bailey EM, Lamp KC, Kaatz GW. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother 1992;36(5):1109-14. 59. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998;54(8):621-5. 60. Guay DR, Vance-Bryan K, Gilliland S, Rodvold K, Rotschafer J. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol 1993;33(10):918-22. 61. Dipiro J, Blouin R, Pruemer J, Spruill W. Concept in clinical pharmacokinetics. 2 ed: American society of health-system pharmacists,Inc.; 1996. 62. Abbott AXSYM vancomycin Ⅱ. 2003. 63. Ambrose PJ, Winter ME. Creatinine clearance. In: Winter ME, ed. Basic clinical pharmacokinetics. 4 ed. Philadelphia: Lippincott Williams & Wilkins; 2004:97-110. 64. Shargel L, Yu A. Dosage adjustment in renal and hepatic disease. In: Shargel L, Yu A, eds. Applied biopharmaceutics and pharmacokinetics. 4 ed: McGraw-Hill; 1999:531-71. 65. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1):31-41. 66. Robert S, Zarowitz BJ, Peterson EL, Dumler F. Predictability of creatinine clearance estimates in critically ill patients. Crit Care Med 1993;21(10):1487-95. 67. Bertino JS, Jr. Measured versus estimated creatinine clearance in patients with low serum creatinine values. Ann Pharmacother 1993;27(12):1439-42. 68. Smythe M, Hoffman J, Kizy K, Dmuchowski C. Estimating creatinine clearance in elderly patients with low serum creatinine concentrations. American journal of hospital pharmacy 1994;51(2):198-204. 69. Spinler SA, Nawarskas JJ, Boyce EG, Connors JE, Charland SL, Goldfarb S. Predictive performance of ten equations for estimating creatinine clearance in cardiac patients. Iohexol Cooperative Study Group. Ann Pharmacother 1998;32(12):1275-83. 70. Mulla H, Nabi F, Nichani S, Lawson G, Firmin RK, Upton DR. Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation. Br J Clin Pharmacol 2003;55(1):23-31. 71. Hoie EB, Swigart SA, Leuschen MP, et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin Pharm 1990;9(9):711-5. 72. Buck ML. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 1998;18(5):1082-6. 73. Rosner B. Hypothesis testing: Two-sample inference. In: Rosner B, ed. Fundamentals of biostatistics. 6 ed; 2006:296-358. 74. Schaad UB, McCracken GH, Jr., Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. The Journal of pediatrics 1980;96(1):119-26. 75. Huang PC, You SL, Lin YM, Chu CL. Body weight of Chinese adults by sex, age and body height and criterion of obesity based on body mass index. J Chinese Nutri Soc 1992;17:157-72. 76. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. The American journal of medicine 1988;84(6):1053-60. 77. DuBois D, DuBois E. A formula to estimate the approximate surface area if height and weight be known. Archives of internal medicine 1916;17:863-71. 78. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. Journal of pharmacokinetics and biopharmaceutics 1976;4(2):183-95. 79. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. Journal of pharmacokinetics and biopharmaceutics 1981;9(4):503-12. 80. Naqvi SH, Keenan WJ, Reichley RM, Fortune KP. Vancomycin pharmacokinetics in small, seriously ill infants. American journal of diseases of children (1960) 1986;140(2):107-10. 81. Capparelli EV, Lane JR, Romanowski GL, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol 2001;41(9):927-34. 82. Brans YW. Body fluid compartments in neonates weighing 1000 grams or less. Clinics in perinatology 1986;13(2):403-17. 83. Del Mar Fernandez de Gatta Garcia M, Revilla N, Calvo MV, Dominguez-Gil A, Sanchez Navarro A. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2006. 84. Many M, Soroff HS, Birtwell WC, Wise HM, Deterling RA, Jr. The physiologic role fo pulsatile and nonpulsatile blood flow. 3. Effects of unilateral renal artery depulsation. Arch Surg 1968;97(6):917-23. 85. Smith HG, Whittlesey GC, Kundu SK, et al. Regional blood flow during extracorporeal membrane oxygenation in lambs. ASAIO transactions / American Society for Artificial Internal Organs 1989;35(3):657-60. 86. Tam VH, Moore GE, Triller DM, Briceland LL. Vancomycin peak serum concentration monitoring. J Intraven Nurs 1999;22(6):336-42. 87. Rybak MJ, Boike SC. Individualized adjustment of vancomycin dosage: comparison with two dosage nomograms. Drug intelligence & clinical pharmacy 1986;20(1):64-8. 88. Rotschafer JC, Crossley K, Zaske DE, Mead K, Sawchuk RJ, Solem LD. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982;22(3):391-4. 89. 王耀輝. 台大醫院病人群vancomycin靜脈輸注起使給藥模式之研究. 國立台灣大學臨床藥學研究所 1997:1-91. 90. Hood B, Attman PO, Ahlmen J, Jagenburg R. Renal hemodynamics and limitations of creatinine clearance in determining filtration rate in glomerular disease. Scandinavian journal of urology and nephrology 1971;5(2):154-61. 91. Moellering RC, Jr., Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981;94(3):343-6. 92. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO, Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982;21(4):575-80. 93. Mohammedi I, Descloux E, Argaud L, Le Scanff J, Robert D. Loading dose of vancomycin in critically ill patients: 15 mg/kg is a better choice than 500 mg. International Journal of Antimicrobial Agents 2006;27(3):259-62. 94. McKindley DS, Fabian TC, Boucher BA, Croce MA, Proctor KG. Antibiotic pharmacokinetics following fluid resuscitation from traumatic shock. Arch Surg 1995;130(12):1321-8; discussion 8-9. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/30997 | - |
dc.description.abstract | 目的:
體外膜氧合術(extracorporeal membrane oxygenation、ECMO)主要是用在預期性可恢復的心肺衰竭病人。由於多重抗藥性的金黃色葡萄球菌(MRSA)的感染日益增加,vancomycin經常用在ECMO的病人作為感染的預防及治療。ECMO在使用時需要外加液體(priming volume),而使用ECMO的病人其腎功能可能變差,加上vancomycin也會吸附在ECMO的管路上而造成損失。因此本研究的目的為研究ECMO在成人的使用是否會對vancomycin的藥品動態學(pharmacokinetics)產生影響,並進一步找出vancomycin在使用ECMO的成人及加護病房(intensive care unit、ICU)病人的給藥建議及峰濃度(Cpeak)的最適當抽血時間。 方法: 本研究收入ECMO及control兩組病人,每組各12位病人。ECMO組病人的收納條件為大於等於18歲使用vancomycin的ECMO病人,如果同時接受連續性靜脈取代療法(continuous renal replacement therapy、CRRT)、血液透析(hemodialysis、HD)及嚴重燒傷的病人(> 30-40 % BSA)則排除。Control組的收納及排除條件和ECMO組的病人相同,除了ECMO的使用之外,且將兩組的年齡、性別及腎功能配對(match),使兩組病人在這些因子的分佈相似。 Vancomycin的給法方面,可選擇給予15 mg/kg的起始劑量,維持劑量依Rodvold法給予,如果病人腎功能正常(CLCr ≥ 50 mL/min)也可給予500 mg q6h或1000 mg q12h的維持劑量。在第四劑(或更多劑)給藥後開始抽取病人血中vancomycin濃度,依據給藥間隔的不同,每個病人抽5-9個點的血中濃度,並利用non-compartment model來分析PK parameters。 利用Sawchuk and Zaske’s method所得到的PK parameters和Non-compartment model 得到的PK parameters的相關性來決定Cpeak的最適當抽血時間。 結果及討論: ECMO及control兩組的k :0.088 ± 0.055 vs. 0.125 ± 0.096 hr-1、t1/2:11.13 ± 9.08 vs. 10.15 ± 9.08 hr、CL:1.18 ± 0.71 vs. 1.45 ± 0.82 mL/min/kg及Vss:0.84 ± 0.24 vs. 0.83 ± 0.30 L/kg,並沒有統計上顯著的差異。Priming volume對於vancomycin Vd的影響並沒有臨床上的意義,而在使用ECMO的病人,其腎臟灌流會減少而導致CLvancomycin的減少,t1/2的增加。將ECMO分為離心式及滾輪式幫浦來分析,兩種幫浦的藥品動態學和各別的control組相比結果同上。比較兩種血液幫浦,使用滾輪式幫浦的病人其k顯著的較小(0.110 ± 0.057 vs. 0.049 ± 0.021, p=0.035), t1/2顯著的較大(7.99 ± 3.88 vs. 16.62 ± 8.30, p=0.04。使用滾輪式幫浦的病人Vss也較大,然未達統計意義。 CLCr和CLvancomycin有顯著的線性關係,以全部病人的資料來分析可得到:CLvancomycin = 0.019*CLCr – 0.18 (r=0.73,R2= 0.53,p <0.001),而將兩組病人分開分析,在control組的病人(r = 0.78)其線性關係較ECMO組的病人(r = 0.61)要好。 Vancomycin在ICU病人(CLCr ≥ 40 mL/min/1.73m2)的使用,建議以15 mg/kg給予病人起始劑量,並以maintenance dose (mg/kg/24hr) = 0.5472*CLCr (mL/min/1.73m2) – 5.184估算病人的維持劑量,以CLCr (mL/min/1.73m2)來決定病人的τ (hrs),CLCr ≥ 100、τ = 6,80 ≤ CLCr ≤ 99、τ =8、40 ≤ CLCr ≤ 79、τ =12。或是以CL(mL/min/kg) = 0.019*CLCr(mL/min/1.73m2) – 0.18;k (hr-1) = 0.0017*CLCr (mL/min/1.73m2) – 0.029、Vd (L/kg)= CL*60/(k*1000) 來預測ICU病人的PK parameters,並藉由此預測的PK parameters估算病人所需的劑量。 建議在給vancomycin至少四個劑量後對病人進行血中濃度監測,由於在ECMO的病人其CLCr和CLvancomycin的線性相關性較差,因此對於使用ECMO的病人可以更早做濃度監測,之後藉由濃度監測所獲得的PK parameters來調整vancomycin的劑量。不管有無使用ECMO的病人皆建議以藥品輸注結束後2小時的血中濃度作為Cpeak。如此可使SZ method得到的PK parameters有較好的預測性。之後根據SZ method所獲得的PK parameters來調整各個病人的vancomycin劑量以達到較適當的治療。 關鍵字:萬古黴素、藥品動態學(藥動學)、體外膜氧合術、重症照護、劑量學、成人 | zh_TW |
dc.description.abstract | Aims:
Extracoporeal membrane oxygenation (ECMO) is indicated for patients with reversible cardiopulmonary failure. Due to the increasing infection rate of methicillin-resistant staphylococcus aureus (MRSA), vancomycin is often empirically used in patients receiving ECMO. Patients on ECMO required priming fluid (centrifugal pump: 850 mL, roller pump: 2000 mL). Studies showed that renal function in patients receiving ECMO altered transiently and vancomycin might be sequestrated by the circuit of ECMO. The objective of this study was to understand the effects of ECMO on pharmacokinetics of vancomycin in adult patients, so as to establish a dosing guildline for patients on ECMO and in ICU and decide the appropriate sampling time for monitoring peak concentration. Methods: This is a control study. Both ECMO and control groups recruited 12 patients. The inclusion criteria for ECMO group were patients greater than or equaled to 18 years-old and received ECMO and vancomycin simultaneously. Those who were on continuous renal replacement therapy (CRRT) or hemodialysis, or having severe burn (involved 30-40% body surface area) were excluded. The inclusion and exclusion criteria for control group were the same as ECMO group, except that they did not use ECMO. Control group was matched with ECMO group by age, sex and renal function. Vancomycin therapy might be initiated with or without a loading dose (LD) of 15 mg/kg. The maintenance dose was determined by Rodvold method. In patients with a creatinine clearance (CLCr) ≥ 50 mL/min, 500 mg q6h and 1000 mg q12h could be given. Serum vancomycin concentrations were determined after at least the fourth dose. Five to nine samples were taken depending on dosing interval and pharmacokinetic (PK) parameters were determined by fitting the data to non-compartment model. The PK parameters determined by Sawchuk and Zaske’s method were compared with those determined by non-compartment model. Through this comparison, the most appropriate sampling time for routine monitor of peak concentration was determined. Results and Discussion: The elimination rate constant (k), half life (t1/2), clearance (CLvancomycin) and volume distribution at steady state (Vss) of ECMO and control group were 0.088 ± 0.055 vs. 0.125 ± 0.096 hr-1, 11.13 ± 9.08 vs. 10.15 ± 9.08 hr, 1.18 ± 0.71 vs. 1.45 ± 0.82 mL/min/kg, 0.84 ± 0.24 vs. 0.83 ± 0.30 L/kg, respectively, and there was no statistically significant difference between the 2 groups. Priming volume of ECMO did not have important influence on Vss of ECMO. Reducing renal perfusion could reduce CLvancomycin and make t1/2 longer. After stratifing ECMO group according to centrifugal and roller pump, there was a significant difference in k (0.110 ± 0.057 vs. 0.049 ± 0.021, p=0.035) and t1/2 (7.99 ± 3.88 vs. 16.62 ± 8.30, p=0.04). Although Vss tended to be greater in patients using roller pump, there were no statistically significant differences between these 2 groups. There were also no statistically differences in PK parameters between the individual groups and their control. CLCr was a good predictor of CLvancomycin. Linear regression using all patient’s data showed that CLvancomycin = 0.019*CLCr – 0.18 (r=0.73, R2= 0.53, p <0.001). The linear relationship was more significant in control group (r = 0.78) than in ECMO group (r = 0.61). In National Taiwan University Hospital, Rodvold method was used to calculate empirical vancomycin maintenance dose. Due to the poor predictivity of the method, we recommended that a 15 mg/kg loading dose be given and an empirical maintenance dose determined by equation: maintenance dose (mg/kg/24hr) = 0.5472*CLCr (mL/min/1.73m2) – 5.184 developed according to CLCr and CLvancomycin in all patients in this study. The dosing intervals were determined according to CLCr (mL/min/1.73m2) : 6 hrs for CLCr ≥ 100; 8 hrs for 80 ≤ CLCr ≤ 99; 12 hrs for 40 ≤ CLCr ≤ 79. This equation could only be applied to patients with a CLCr greater than 40 mL/min/1.73m2. From this study, PK parameters might be estimated by CL(mL/min/kg) = 0.019*CLCr(mL/min/1.73m2) – 0.18、k(hr-1) = 0.0017*CLCr(mL/min/1.73m2) – 0.029、Vd(L/kg) = CL*60/(k*1000) and used these PK parameters to determine appropriate dose for individual patients. . After empirical dosing of vancomycin, pharmacokinetic monitoring should be performed after at least four doses, especially for patients receiving ECMO. The most appropriate sampling time for peak concentration was 2 hours after completion of infusion of vancomycin. After obtaining peak and trough concentration, Sawchuk and Zaske’s method provides a good estimate of PK parameters for adjusting vancomycin dosage. Key words:vancomycin、pharmacokinetics (PK)、extracoporeal membrane oxygenation (ECMO)、critical care、dosage、adult | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T02:24:34Z (GMT). No. of bitstreams: 1 ntu-96-R93451011-1.pdf: 1392116 bytes, checksum: d7ea5e256d2c6798a9be953acc696fdd (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 內容目錄 I
圖目錄 IV 表目錄 V 中文摘要 VIII Abstract X 縮寫表 XIII 第一章 前言 1 第二章 ECMO、vancomycin、腎絲球過濾速率估計公式的簡介及相關 文獻 3 2.1 體外膜氧合術 (extracorporeal membrane oxygenation、ECMO): 3 2.1.1 體外循環術 (CPB)和體外膜氧合術 (ECMO)的比較: 3 2.1.2 ECMO的型態: 5 2.1.3 ECMO的組成及介紹: 7 2.1.4 ECMO的臨床使用及發展: 9 2.2 Vancomycin 14 2.2.1 藥效學介紹(pharmacodynamic): 14 2.2.2 副作用: 15 2.2.3 藥品動態學(pharmacokinetic、PK): 16 2.2.4 影響藥品動態學的狀態: 21 2.2.5 在臨床上的使用: 23 2.2.6 vancomycin血中濃度之測量及檢體處理: 24 2.3 腎絲球過濾速率(glomerular filtration rate,GFR)的估計公式: 25 2.4 Vancomycin pharmacokinetics in ECMO相關文獻探討: 26 第三章 研究目的及方法 31 3.1 研究目的: 31 3.2 研究方法: 32 3.2.1 病人數(sample size): 32 3.2.2 病人的收納條件 (inclusion criteria): 33 3.2.3 病人的排除條件 (exclusion criteria): 34 3.2.4 ECMO的作業系統: 34 3.2.5 ECMO的建立與使用: 39 3.2.6 試驗的設計: 40 3.2.7 相關數據收集: 41 3.2.8 Vancomycin藥品血中濃度測定: 41 3.2.9 藥品動態學研究: 41 第四章 研究結果 46 4.1 研究時間,地點及病人數: 46 4.2 基本資料: 46 4.3 藥品動態學比較: 54 4.4 SZ method所獲得的PK parameters的預測性及和WinNonlin PK parameters間的相關性: 60 4.5 CLCr和藥品動態學參數間的相關性: 65 4.6 劑量學研究: 70 4.6.1 給藥間隔(τ)的決定: 70 4.6.2 每日維持劑量: 70 第五章 討論 74 5.1 ECMO病人vancomycin藥品動態學分析: 74 5.2 SZ method對PK parameters的預測性以及和WinNonlin PK parameters間的相關性: 79 5.3 CLCr和藥品動態學參數的相關性: 80 5.4 劑量學研究: 83 5.5 研究限制: 84 5.5.1 病人數: 84 5.5.2 對照組病人的選取: 84 5.5.3 公式的效度: 85 第六章 結論 86 Reference 87 附錄一:各個病人的multiple short infusion model及residual plot 94 附錄二:兩組調整前與調整後的藥品動態學參數 140 | |
dc.language.iso | zh-TW | |
dc.title | 使用體外膜氧合術(ECMO)的成人其萬古黴素(vancomycin)藥品動態學及劑量學研究 | zh_TW |
dc.title | Pharmacokinetics and posology of vancomycin in adults receiving ECMO | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-1 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 柯文哲(Wen-Je Ko) | |
dc.contributor.oralexamcommittee | 黃金鼎(Jin-Ding Huang) | |
dc.subject.keyword | 萬古黴素,藥品動態學(藥動學),體外膜氧合術,重症照護,劑量學,成人, | zh_TW |
dc.subject.keyword | vancomycin,pharmacokinetics (PK),extracoporeal membrane oxygenation (ECMO),critical care,dosage,adult, | en |
dc.relation.page | 141 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-01-30 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 1.36 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。